Stocks of Editas Medicine Inc (NASDAQ:EDIT) traded higher last session on Wall Street, up 12.20% to $1.38.
EDIT stock price is now -2.81% away from the 50-day moving average and -60.99% away from the 200-day moving average. The market capitalization of the company currently stands at $113.92M.
, while ‘Stifel’ rates the stock as ‘Hold’
In other news, O’Neill Gilmore Neil, CEO sold 1,618 shares of the company’s stock on Dec 03 ’24. The stock was sold for $3,361 at an average price of $2.08. Upon completion of the transaction, the CEO now directly owns 312,106 shares in the company, valued at $0.43 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 03 ’24, EVP, CHIEF MEDICAL OFFICER Mei Baisong sold 541 shares of the business’s stock. A total of $1,124 was realized by selling the stock at an average price of $2.08. This leaves the insider owning 133,354 shares of the company worth $0.18 million. A total of 0.93% of the company’s stock is owned by insiders.
During the past 12 months, Editas Medicine Inc has had a low of $1.12 and a high of $11.58. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 3.75, and a quick ratio of 3.75. The fifty day moving average price for EDIT is $1.4199 and a two-hundred day moving average price translates $3.537125 for the stock.
The latest earnings results from Editas Medicine Inc (NASDAQ: EDIT) was released for 2024-09-30. The net profit margin was -340.96% and return on equity was -78.56% for EDIT. The company reported revenue of $61000.0 for the quarter, compared to $5.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -98.86 percent.
